U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07179575) titled 'Phase Ib/II Study of LW231 in Chronic Hepatitis B' on Sept. 16.
Brief Summary: This is a Phase Ib/II, multicenter, randomized, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of LW231 in participants with chronic hepatitis B virus (HBV) infection. The trial will include multiple-dose regimens of LW231 and assess LW231 in combination with NUCs.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Chronic HBV Infection
Intervention:
DRUG: LW231
LW231 tablets
DRUG: LW231 placebo
LW231 placebo tablets
Recruitment Status: NOT_YET_RE...